Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis.

CONCLUSION: Our results indicate that intranasal delivery of Fasudil-modified MNCs have therapeutic potential in EAE, providing a safe and effective cell therapeutic strategy to MS and/or other related disorders. PMID: 30779332 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30779332?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - February 18, 2019 Category: Neuroscience Authors: Guo SD, Liu CY, Yu JW, Chai Z, Wang Q, Mi XT, Song GB, Li YH, Yang PW, Feng L, Xiao BG, Ma CG Tags: CNS Neurosci Ther Source Type: research